Correction: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

BMC Psychiatry. 2022 Jun 8;22(1):388. doi: 10.1186/s12888-022-03975-3.

¹ Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Avenue, Lexington, MA, 02421, USA. Maggie.McCue@takeda.com.
² Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Avenue, Lexington, MA, 02421, USA.
³ Lundbeck LLC, 6 Parkway North Blvd, Deerfeld, IL, 60015, USA.
⁴ University of Michigan Health, 1500 E. Medical Center Dr, Ann Arbor, MI, 48109, USA.

Abstract